期刊文献+

含吡啶的抗肿瘤转移NAMI-A衍生物的制备和水解机理动力学 被引量:2

Preparation and Mechanism-Kinetics of Antimetastasis of NAMI-A Derivatives Containing Pyridine
下载PDF
导出
摘要 目的研究配体结构对NAMI-A衍生物水解机理、电化学性质的影响。方法制备了trans-[RuCl4(DMSO)(3-MePy)][(3-MePy)H](3-MePy=3-甲基吡啶,化合物1)和trans-[RuCl4(DMSO)(4-MePy)][(4-MePy)H](4-MePy=4-甲基吡啶,化合物2)。用UV、NMR、CV法研究化合物1、化合物2的水解机理-动力学、溶液稳定性及电化学性质。结果化合物1和化合物2与NAMI-A相似,在pH7.40的缓冲液中发生脱氯水解反应(Ⅰ氯水解及Ⅱ氯水解)(分步反应);在pH 5.00缓冲液中DMSO(二甲亚砜)及少量吡啶水解。测定各水解反应表观速率常数及半衰期、溶液稳定性及氧化还原电位。结论化合物1、化合物2的Ⅰ氯、Ⅱ氯及DMSO水解反应机理与NAMI-A相似,而且各水解速率与NAMI-A相差不大,即用甲基吡啶取代咪唑环,对NAMI-A衍生物的Ⅰ氯、Ⅱ氯及DMSO水解反应速率影响较小。化合物在酸性溶液中的稳定性明显高于中性溶液。 Objective To study the influence of ligand structure on the hydrolysis rate of anti-metastasis NAMI-A derivatives trans-[RuCl4(DMSO)(3-MePy)][(3-MePy)H](3-MePy=3-methypyridine,Compd.1) and trans-[RuCl4(DMSO)(4-MePy)][(4-MePy)H](4-MePy=4-methypyridine,Compd.2).Method Hydrolytic mechanism,kinetics,stability and electrochemistry of Compd.1 and Compd.2 were studied by UV-Vis,NMR and CV.Result The complexes undergo two well-separated steps of chloride hydrolysis at pH 7.40;while dimethyl sulfoxide(DMSO) hydrolyzed in pH 5.00 buffer solution.The Kobs and t1/2 for each reaction were determined.Conclusion Very similar to NAMI-A,the compounds loses 1st and 2nd chloride in two separated steps at pH 7.40;and loses DMSO in pH 5.00 buffer solution.The hydrolytic rate of the compounds including two chlorides and DMSO hydrolysis were similar to that of NAMI-A,which demonstrated that the influence of replacing imidazole by methyl pyridine on the hydrolysis rate of NAMI-A derivatives is not remarkable.The stability of the compounds in acidic solution is much more stable than that of in neutral solution.
出处 《无机化学学报》 SCIE CAS CSCD 北大核心 2011年第4期595-603,共9页 Chinese Journal of Inorganic Chemistry
基金 澳门科技发展基金(No.012/2009/A1) 国家科技部国际合作基金(No.2005DFA30990) 中国中医科学院基本科研业务费自主选题项目(No.ZZ2006120,Z02089)资助
关键词 钌配合物 抗肿瘤转移 水解动力学 稳定性 ruthenium complexes anti-metastasis hydrolytic kinetics stabilities
  • 相关文献

参考文献32

  • 1Sava G, Dyson P J. Dalton Trans., 2006:1929-1933.
  • 2Bouma M, Nuijen B, Jansen M T, et al. Int. J. Pharm., 2002, 248(1/2):239-246.
  • 3Bergamo A, Gava B, Alessio E, et al. Int. J. Oncol., 2002,21 (6):1331-1338.
  • 4Kostova I. Curr. Med. Chem., 2006,13(9):1085-1107.
  • 5Rademaker-Lakhai J M, van den Bongard D, Pluim D, et al. Clin. Cancer Res., 2004,10(11):3717-3727.
  • 6Casini A, Mastrobuoni G, Terenghi M, et al. J. Biol. Inorg. Chem., 2007,12(8):1107-1117.
  • 7Bratsos I, Bergamo A, Sara G, et al. J. Inorg. Biochem., 2008, 102(4):606-617.
  • 8Bacac M, Hotze A C, van der Schilden K, et al. J. Inorg. Biochem., 2004,98(2):402-412.
  • 9Messori L, Orioli P, Vullo D, et al. Eur. J. Biochem., 2000, 267(4):1206-1213.
  • 10Frausin F, Scarcia V, Cocchietto M, et al. J. Pharmacol. Exp. Ther., 2005,313(1):227-233.

同被引文献6

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部